AI Article Synopsis

  • The study examined the changes in antibody levels in healthcare workers after receiving two doses of the BNT162b2 mRNA COVID-19 vaccine, measuring specific IgG and neutralizing antibodies at various time points.
  • Anti-RBD IgG levels showed a significant decline over time, decreasing by 4.5 times at 3 months and 13 times at 6 months, while anti-Trimeric S IgG levels decreased less dramatically, suggesting different decay rates for these antibody types.
  • The findings indicate complex dynamics of antibody maturation post-vaccination and highlight the challenges in establishing reliable protection markers due to inconsistent laboratory standards.

Article Abstract

To investigate the dynamic association among binding and functional antibodies in health-care-workers receiving two doses of BNT162b2 mRNA COVID-19-vaccine, SARS-CoV-2 anti-RBD IgG, anti-Trimeric-S IgG, and neutralizing antibodies (Nabs) were measured in serum samples collected at 2 weeks, 3 months, and 6 months from full vaccination. Despite the high correlation, results for anti-RBD and anti-Trimeric S IgG were numerically different even after recalculation to BAU/mL following WHO standards indications. Moreover, after a peak response at 2 weeks, anti-RBD IgG levels showed a 4.5 and 13 fold decrease at 3 and 6 months, respectively, while the anti-Trimeric S IgG presented a less pronounced decay of 2.8 and 4.7 fold. Further different dynamics were observed for Nabs titers, resulting comparable at 3 and 6 months from vaccination. We also demonstrated that at NAbs titers ≥40, the area under the receiver operating characteristic curve and the optimal cutoff point decreased with time from vaccination for both anti-RBD and anti-Trimeric S IgG. The mutating relation among the anti-RBD IgG, anti-Trimeric S IgG, and neutralizing antibodies are indicative of antibody maturation upon vaccination. The lack of standardized laboratory procedures is one factor interfering with the definition of a correlate of protection from COVID-19.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878369PMC
http://dx.doi.org/10.3390/v14020312DOI Listing

Publication Analysis

Top Keywords

anti-trimeric igg
16
anti-rbd igg
12
binding functional
8
functional antibodies
8
igg
8
igg neutralizing
8
neutralizing antibodies
8
anti-rbd anti-trimeric
8
nabs titers
8
anti-rbd
5

Similar Publications

The role and durability of the immunogenicity of the BNT162b2 mRNA vaccine against severe acute respiratory virus 2 (SARS-CoV-2), in cancer patients one year after receiving the third dose have to be elucidated. We have prospectively evaluated the long-term immunogenicity of the third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in 55 patients undergoing active treatment. Neutralizing antibody (NT Ab) titers against Omicron variants and total anti-trimeric S IgG levels were measured one year after the third dose.

View Article and Find Full Text PDF

Accurate studies on the dynamics of Pfizer-Biontech BNT162b2-induced antibodies are crucial to better tailor booster dose administration depending on age, comorbidities, and previous natural infection with SARS-CoV-2. To date, little is known about the durability and kinetics of antibody titers months after receiving a booster dose. In this work, we studied the dynamic of anti-Trimeric Spike (anti-TrimericS) IgG titer in the healthcare worker population of a large academic hospital in Northern Italy, in those who had received two vaccine doses plus a booster dose.

View Article and Find Full Text PDF

Changing Patterns of SARS-CoV-2 Seroprevalence: A Snapshot among the General Population in Kuwait.

Vaccines (Basel)

February 2023

Microbiology Unit, Department of Laboratory Medicine, Farwania Hospital, Ministry of Health, Kuwait City 85000, Kuwait.

We sought to assess pre-vaccination and post-vaccination seroprevalences of anti-SARS-CoV-2 antibodies in Kuwait and to compare antibody levels between vaccine types. In phase 1 (pre-vaccination period, = 19,363), blood samples were collected before the launch of COVID-19 vaccination in Kuwait between 1 September and 31 December 2020. Blood samples for phase 2 (post-vaccination period, = 4973) were collected between 1 September and 30 November 2021.

View Article and Find Full Text PDF

Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement Therapy.

Vaccines (Basel)

August 2022

Renal Division, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, Italy.

Patients with CKD on RRT are at high risk for severe disease and mortality in COVID-19 disease. We decided to conduct an observational prospective study to evaluate antibody response after vaccination for COVID-19 in a cohort of 210 adult patients on RRT (148 on HD; 20 on PD; and 42 kidney transplant recipients). Blood samples were taken before and 4 weeks after vaccination.

View Article and Find Full Text PDF

Humoral immunity induced by mRNA COVID-19 vaccines in Nursing Home Residents previously infected with SARS-CoV-2.

Aging Clin Exp Res

October 2022

Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, Rome, Italy.

Background: Nursing home (NH) residents suffered the greatest impact of the COVID-19 pandemic. Limited data are available on vaccine-induced immunity and on the protection ensured by a prior infection in this population.

Aims: The present study aims to monitor antibody levels and their persistence over a 6-month period in NH residents according to the history of prior SARS-CoV-2 infection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!